Suzhou Abogen Biosciences | Evaluate

Orbital shows 2023’s venture funding scene is far from stratospheric

The group’s $270m series A, big for 2023, is not that impressive compared with other years.

January 05, 2022

In 2021 it paid to stay private when the chips were down

While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.

October 12, 2021

Another big year beckons for biotech venture financing

Private drug developers have already raised more money this year than in 2020.